Multiple Sclerosis Journal - Experimental, Translational and Clinical最新文献

{"title":"Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.","authors":"Lars Forsberg,&nbsp;Tim Spelman,&nbsp;Pernilla Klyve,&nbsp;Ali Manouchehrinia,&nbsp;Ryan Ramanujam,&nbsp;Elena Mouresan,&nbsp;Jiri Drahota,&nbsp;Dana Horakova,&nbsp;Hanna Joensen,&nbsp;Luigi Pontieri,&nbsp;Melinda Magyari,&nbsp;David Ellenberger,&nbsp;Alexander Stahmann,&nbsp;Jeff Rodgers,&nbsp;James Witts,&nbsp;Rod Middleton,&nbsp;Richard Nicholas,&nbsp;Vladimir Bezlyak,&nbsp;Nicholas Adlard,&nbsp;Thomas Hach,&nbsp;Carol Lines,&nbsp;Sandra Vukusic,&nbsp;Merja Soilu-Hänninen,&nbsp;Anneke van der Walt,&nbsp;Helmut Butzkueven,&nbsp;Pietro Iaffaldano,&nbsp;Maria Trojano,&nbsp;Anna Glaser,&nbsp;Jan Hillert","doi":"10.1177/20552173231153557","DOIUrl":"https://doi.org/10.1177/20552173231153557","url":null,"abstract":"<p><strong>Background: </strong>To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease course classification may give a better estimation of the relative proportions of relapsing-remitting MS (RRMS) and SPMS and may identify situations where SPMS is under reported.</p><p><strong>Materials and methods: </strong>Data were obtained for 61,900 MS patients from MS registries in the Czech Republic, Denmark, Germany, Sweden, and the United Kingdom (UK), including date of birth, sex, SP conversion year, visits with an Expanded Disability Status Scale (EDSS) score, MS onset and diagnosis date, relapses, and disease-modifying treatment (DMT) use. We included RRMS or SPMS patients with at least one visit between January 2017 and December 2019 if ≥ 18 years of age. We applied three objective methods: A set of SPMS clinical trial inclusion criteria (\"EXPAND criteria\") modified for a real-world evidence setting, a modified version of the MSBase algorithm, and a decision tree-based algorithm recently published.</p><p><strong>Results: </strong>The clinically assigned proportion of SPMS varied from 8.7% (Czechia) to 34.3% (UK). Objective classifiers estimated the proportion of SPMS from 15.1% (Germany by the EXPAND criteria) to 58.0% (UK by the decision tree method). Due to different requirements of number of EDSS scores, classifiers varied in the proportion they were able to classify; from 18% (UK by the MSBase algorithm) to 100% (the decision tree algorithm for all registries). Objectively classified SPMS patients were older, converted to SPMS later, had higher EDSS at index date and higher EDSS at conversion. More objectively classified SPMS were on DMTs compared to the clinically assigned.</p><p><strong>Conclusion: </strong>SPMS appears to be systematically underdiagnosed in MS registries. Reclassified patients were more commonly on DMTs.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 1","pages":"20552173231153557"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10762423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New algorithmic approach for easier and faster extended disability status scale calculation.","authors":"Amr M Fouad,&nbsp;Maged Abdel Naseer,&nbsp;Marwa Farghaly,&nbsp;Mohamed I Hegazy","doi":"10.1177/20552173231155055","DOIUrl":"https://doi.org/10.1177/20552173231155055","url":null,"abstract":"<p><strong>Background: </strong>The traditional paper and pencil method for EDSS calculation (pEDSS) is the cornerstone of multiple sclerosis practice; however, it requires an expert for an accurate calculation, and it takes a lot of time to perform the function scores. A new algorithmic approach (aEDSS) has been developed for easier and faster assessment.</p><p><strong>Objective: </strong>To determine if using aEDSS can achieve good inter-rater agreement and save time compared to pEDSS.</p><p><strong>Subjects and methods: </strong>This study was conducted on 200 MS patients; EDSS was performed twice for each patient by two neurologists on the same day; one used the pEDSS, and the other used the aEDSS in a random order to test the inter-rater agreement regarding functional system scores and the final EDSS score and to detect the difference in the time needed for calculation between both methods.</p><p><strong>Results: </strong>The new algorithmic approach achieved excellent agreement with the traditional method (Kappa > 0.81) with a shorter calculation time (16 ± 2.67 min for aEDSS vs 31 ± 4.3 min for pEDSS, <i>P</i> < 0.0001).</p><p><strong>Conclusion: </strong>The new algorithmic approach could represent a suitable alternative to the traditional method, making EDSS calculation easier and faster.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 1","pages":"20552173231155055"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/69/10.1177_20552173231155055.PMC9936401.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10762424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment.","authors":"Tommi Tervonen,&nbsp;Robert J Fox,&nbsp;Anne Brooks,&nbsp;Tatiana Sidorenko,&nbsp;Neli Boyanova,&nbsp;Bennett Levitan,&nbsp;Brian Hennessy,&nbsp;Andrea Phillips-Beyer","doi":"10.1177/20552173221150370","DOIUrl":"https://doi.org/10.1177/20552173221150370","url":null,"abstract":"<p><strong>Background: </strong>Treatment decisions for multiple sclerosis (MS) are influenced by many factors such as disease symptoms, comorbidities, and tolerability.</p><p><strong>Objective: </strong>To determine how much relapsing MS patients were willing to accept the worsening of certain aspects of their MS in return for improvements in symptoms or treatment convenience.</p><p><strong>Methods: </strong>A web-based discrete choice experiment (DCE) was conducted in patients with relapsing MS. Multinomial logit models were used to estimate relative attribute importance (RAI) and to quantify attribute trade-offs.</p><p><strong>Results: </strong>The DCE was completed by 817 participants from the US, the UK, Poland, and Russia. The most valued attributes of MS therapy to participants were effects on physical fatigue (RAI = 22.3%), cognitive fatigue (RAI = 22.0%), relapses over 2 years (RAI = 20.7%), and MS progression (RAI = 18.4%). Participants would accept six additional relapses in 2 years and a decrease of 7 years in time to disease progression to improve either cognitive or physical fatigue from \"quite a bit of difficulty\" to \"no difficulty.\"</p><p><strong>Conclusion: </strong>Patients strongly valued improving cognitive and physical fatigue and were willing to accept additional relapses or a shorter time to disease progression to have less fatigue. The impact of fatigue on MS patients' quality of life should be considered in treatment decisions.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 1","pages":"20552173221150370"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1d/72/10.1177_20552173221150370.PMC9880588.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10583782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.","authors":"Colin M Dayan,&nbsp;Beatriz Lecumberri,&nbsp;Ilaria Muller,&nbsp;Sashiananthan Ganesananthan,&nbsp;Samuel F Hunter,&nbsp;Krzysztof W Selmaj,&nbsp;Hans-Peter Hartung,&nbsp;Eva K Havrdova,&nbsp;Christopher C LaGanke,&nbsp;Tjalf Ziemssen,&nbsp;Bart Van Wijmeersch,&nbsp;Sven G Meuth,&nbsp;David H Margolin,&nbsp;Elizabeth M Poole,&nbsp;Darren P Baker,&nbsp;Peter A Senior","doi":"10.1177/20552173221142741","DOIUrl":"https://doi.org/10.1177/20552173221142741","url":null,"abstract":"<p><strong>Background: </strong>Alemtuzumab is an effective therapy for relapsing multiple sclerosis. Autoimmune thyroid events are a common adverse event.</p><p><strong>Objective: </strong>Describe endocrine and multiple sclerosis outcomes over 6 years for alemtuzumab-treated relapsing multiple sclerosis patients in the phase 3 CARE-MS I, II, and extension studies who experienced adverse thyroid events.</p><p><strong>Methods: </strong>Endocrine and multiple sclerosis outcomes were evaluated over 6 years. Thyroid event cases, excluding those pre-existing or occurring after Year 6, were adjudicated retrospectively by expert endocrinologists independently of the sponsor and investigators.</p><p><strong>Results: </strong>Thyroid events were reported for 378/811 (46.6%) alemtuzumab-treated patients. Following adjudication, endocrinologists reached consensus on 286 cases (75.7%). Of these, 39.5% were adjudicated to Graves' disease, 2.5% Hashimoto's disease switching to hyperthyroidism, 15.4% Hashimoto's disease, 4.9% Graves' disease switching to hypothyroidism, 10.1% transient thyroiditis, and 27.6% with uncertain diagnosis; inclusion of anti-thyroid antibody status reduced the number of uncertain diagnoses. Multiple sclerosis outcomes of those with and without thyroid events were similar.</p><p><strong>Conclusion: </strong>Adjudicated thyroid events occurring over 6 years for alemtuzumab-treated relapsing multiple sclerosis patients were primarily autoimmune. Thyroid events were considered manageable and did not affect disease course. Thyroid autoimmunity is a common but manageable adverse event in alemtuzumab-treated relapsing multiple sclerosis patients.<b>ClinicalTrials.gov Registration Numbers:</b> CARE-MS I (NCT00530348); CARE-MS II (NCT00548405); CARE-MS Extension (NCT00930553).</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 1","pages":"20552173221142741"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/3b/10.1177_20552173221142741.PMC9817015.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10509518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis.","authors":"Mitchell J Lycett,&nbsp;Rodney A Lea,&nbsp;Vicki E Maltby,&nbsp;Myintzu Min,&nbsp;Jeannette Lechner-Scott","doi":"10.1177/20552173221149688","DOIUrl":"https://doi.org/10.1177/20552173221149688","url":null,"abstract":"<p><strong>Background: </strong>Cladribine is a useful therapeutic option in RRMS with moderate to high disease activity. Its oral formulation and tolerability make it a useful alternative to infusion therapies. Cladribine is known to deplete CD19⁺ B lymphocytes, but its effect on immunoglobulin subsets is unclear.</p><p><strong>Objective: </strong>To identify whether cladribine therapy in pwMS reduces immunoglobulin subset levels as a surrogate marker of infection risk.</p><p><strong>Methods: </strong>A 'real-world' retrospective analysis of 341 pwMS presenting to a single tertiary centre between March 2017 and July 2021. Differences in immunoglobulin levels between cladribine, other disease-modifying therapies and no active treatment were assessed using a univariate ANOVA.</p><p><strong>Results: </strong>Three hundred and forty-one patients had immunoglobulin levels assessed, with 29 patients treated with cladribine. The mean IgG, IgM and IgA levels on cladribine therapy were 10.44 ± 0.40, 0.99 ± 0.09 and 2.04 ± 0.18 g/L respectively. These were not significantly different from patients not on active treatment. There was a statistically significant reduction in IgG and IgM levels for patients treated with ocrelizumab (9.37 ± 0.19 and 0.68 ± 0.04 g/L) and natalizumab (8.72 ± 0.53 and 0.69 ± 0.12 g/L) compared to patients not on treatment.</p><p><strong>Conclusion: </strong>Cladribine therapy for RRMS was not associated with immunoglobulin subset deficiencies. This is contrasted to ocrelizumab and natalizumab which demonstrate significant reductions in both IgG and IgM levels.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 1","pages":"20552173221149688"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/c4/10.1177_20552173221149688.PMC9830094.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10519505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CORRIGENDUM to Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate.","authors":"","doi":"10.1177/20552173231160312","DOIUrl":"https://doi.org/10.1177/20552173231160312","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/20552173221132469.].</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 1","pages":"20552173231160312"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/5b/10.1177_20552173231160312.PMC9974626.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10828606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower corticospinal excitability and greater fatigue among people with multiple sclerosis experiencing pain.","authors":"Hannah M Murphy,&nbsp;Christopher M Fetter,&nbsp;Nicholas J Snow,&nbsp;Arthur R Chaves,&nbsp;Matthew B Downer,&nbsp;Michelle Ploughman","doi":"10.1177/20552173221143398","DOIUrl":"https://doi.org/10.1177/20552173221143398","url":null,"abstract":"<p><strong>Introduction: </strong>Persons with multiple sclerosis (MS) frequently report pain that negatively affects their quality of life. Evidence linking pain and corticospinal excitability in MS is sparse. We aimed to (1) examine differences in corticospinal excitability in MS participants with and without pain and (2) explore predictors of pain.</p><p><strong>Methods: </strong>Sixty-four participants rated their pain severity on a visual analog scale (VAS). Transcranial magnetic stimulation (TMS) and validated clinical instruments characterized corticospinal excitability and subjective disease features like mood and fatigue. We retrieved information on participants' prescriptions and disability status from their clinical records.</p><p><strong>Results: </strong>Fifty-five percent of participants reported pain that affected their daily functioning. Persons with pain had significantly greater fatigue and lower area under the excitatory motor evoked potential (MEP) recruitment curve (eREC AUC), a measure of total corticospinal excitability. After controlling for age, disability status, and pain medications, increased fatigue and decreased eREC AUC together explained 40% of the variance in pain.</p><p><strong>Discussion: </strong>Pain in MS is multifactorial and relates to both greater fatigue and lesser corticospinal excitability. Future work should better characterize relationships between these outcomes to develop targeted pain interventions such as neuromodulation.</p><p><strong>Summary: </strong>We examined pain in MS. Individuals with pain had higher fatigue and lower corticospinal excitability than those without pain. These outcomes significantly predicted self-reported pain.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 1","pages":"20552173221143398"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10519077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High fever in myelin oligodendrocyte glycoprotein-associated disorder (MOGAD): A diagnostic challenge.","authors":"Chadi Azar,&nbsp;Grace Akiki,&nbsp;Sara F Haddad,&nbsp;Anthony Kerbage,&nbsp;Fady Haddad,&nbsp;Gabrielle Macaron","doi":"10.1177/20552173221148911","DOIUrl":"https://doi.org/10.1177/20552173221148911","url":null,"abstract":"<p><p>The phenotypic spectrum of myelin oligodendrocyte glycoprotein (MOG)-IgG associated disorders (MOGAD) has broadened in the past few years, and atypical phenotypes are increasingly recognized. Febrile meningoencephalitis has rarely been reported as a feature of MOGAD and represents a diagnostic challenge. We report the case of 24-year-old women with high-grade fever, meningoencephalomyelitis, and persistently positive MOG-IgG, for whom an extensive infectious work-up was negative and who responded to high-dose intravenous methylprednisolone. The full clinical spectrum of MOGAD is yet to be completely elucidated. In patients presenting with febrile meningoencephalitis, MOG-IgG testing should be considered particularly if infectious work-up is negative.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 1","pages":"20552173221148911"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/73/10.1177_20552173221148911.PMC9830568.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10519506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between brain volume and disability over time in multiple sclerosis.","authors":"Thomas Moridi,&nbsp;Leszek Stawiarz,&nbsp;Kyla A McKay,&nbsp;Benjamin V Ineichen,&nbsp;Russell Ouellette,&nbsp;Daniel Ferreira,&nbsp;J-Sebastian Muehlboeck,&nbsp;Eric Westman,&nbsp;Ingrid Kockum,&nbsp;Tomas Olsson,&nbsp;Fredrik Piehl,&nbsp;Jan Hillert,&nbsp;Ali Manouchehrinia,&nbsp;Tobias Granberg","doi":"10.1177/20552173221144230","DOIUrl":"https://doi.org/10.1177/20552173221144230","url":null,"abstract":"<p><strong>Background: </strong>Most previous multiple sclerosis (MS) brain atrophy studies using MS impact scale 29 (MSIS-29) or symbol digit modalities test (SDMT) have been cross-sectional with limited sets of clinical outcomes.</p><p><strong>Objectives: </strong>To investigate which brain and lesion volume metrics show the strongest long-term associations with the expanded disability status scale (EDSS), SDMT, and MSIS-29, and whether MRI-clinical associations vary with age.</p><p><strong>Methods: </strong>We acquired MRI and clinical data from a real-world Swedish MS cohort. FreeSurfer and SPM Lesion Segmentation Tool were used to obtain brain parenchymal, cortical and subcortical grey matter, thalamic and white matter fractions as well as T₁- and T₂-lesion volumes. Mixed-effects and rolling regression models were used in the statistical analyses.</p><p><strong>Results: </strong>We included 989 persons with MS followed for a median of 9.3 (EDSS), 10.1 (SDMT), and 9.3 (MSIS-29) years, respectively. In a cross-sectional analysis, the strength of the associations of the MRI metrics with the EDSS and MSIS-29 was found to drastically increase after 40-50 years of age. Low baseline regional grey matter fractions were associated with longitudinal increase of EDSS and physical MSIS-29 scores and decrease in SDMT scores and these atrophy measures were stronger predictors than the lesion volumes.</p><p><strong>Conclusions: </strong>The strength of MRI-clinical associations increase with age. Grey matter volume fractions are stronger predictors of long-term disability measures than lesion volumes.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"8 4","pages":"20552173221144230"},"PeriodicalIF":2.8,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10787347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personality traits are not associated with changes in employment status over 3 years in persons with multiple sclerosis.","authors":"K van der Hiele,&nbsp;Eea van Egmond,&nbsp;Dam van Gorp,&nbsp;P J Jongen,&nbsp;M F Reneman,&nbsp;Jjl van der Klink,&nbsp;Eac Beenakker,&nbsp;Jjj van Eijk,&nbsp;Stfm Frequin,&nbsp;E Hoitsma,&nbsp;Ohh Gerlach,&nbsp;J P Mostert,&nbsp;Wim Verhagen,&nbsp;Map Heerings,&nbsp;Ham Middelkoop,&nbsp;L H Visser","doi":"10.1177/20552173221145576","DOIUrl":"https://doi.org/10.1177/20552173221145576","url":null,"abstract":"<p><p>Previous research discovered a protective effect of higher conscientiousness against a 3-year deterioration in employment status in persons with multiple sclerosis (pwMS). To replicate these findings, we used data from a multicentre prospective cohort study where 145 employed pwMS completed questionnaires, neurological and neuropsychological examinations at baseline and after 3 years. A 3-year deterioration in employment status was reported in 31.0%. We observed no differences in personality, demographics or clinical characteristics between pwMS with deteriorated or stable employment status. These null findings may be partly explained by the classification of deteriorated employment status, which does not reflect Dutch labour conditions.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"8 4","pages":"20552173221145576"},"PeriodicalIF":2.8,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10787349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}